source
- Relay Therapeutics reports promising Phase 2 results for zovegalisib; Eli Lilly leads R&D performance rankingRelay Therapeutics announced positive Phase 2 data for its experimental drug zovegalisib, which targets rare diseases that cause abnormal blood vessel development. The company said the results were…
- Relay Therapeutics' zovegalisib shows 60% response in mid‑stage trial for rare vascular anomaliesRelay Therapeutics reported early data from a phase 2 trial of its experimental drug zovegalisib in patients with vascular anomalies, a group of rare disorders characterized by abnormal blood vesse…